MRx-102

N/A

Report date: 2024/11/20 14:15:24

NME

Base Information

Drug NameMRx-102

Drug Alias NameMRx-102

ClassificationSmall molecules > Heterocyclic drugs

Mechanisms of ActionCatenin beta 1 inhibitorsInduced myeloid leukemia cell differentiation protein Mcl-1 inhibitorsInhibitor of apoptosis protein 3 inhibitors

TargetsCatenin beta 1Induced myeloid leukemia cell differentiation protein Mcl-1Inhibitor of apoptosis protein 3

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPending (Preclinical)

Highest Status in ChinaN/A

Originator CompaniesThe University Of Texas MD Anderson Cancer Center

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesThe University Of Texas MD Anderson Cancer Center

Active IndicationsN/A

Inactive IndicationsLeukemia, Myeloid, Acute

Other Information

ATC CodeN/A